Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2011

01-12-2011 | Original paper

Pegfilgrastim overdose: case report and review of the literature

Authors: Orit Kaidar–Person, Mor Moskovitz, Tomer Charas, Wasim Alsharbati, Nissim Haim

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

Single-dose pegfilgrastim is commonly used for the prophylaxis of neutropenia in patients receiving myelotoxic chemotherapy. We report a case of a 69-year-old man who was treated with chemotherapy for small-cell lung cancer and mistakenly self-administered a 36 mg overdose of pegfilgrastim, a sixfold increase over the scheduled dose.
Literature
1.
2.
Martinez C, et al. Efficacy and toxicity of high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 1999;24:1273–8.PubMedCrossRef
3.
Pitini V, et al. Spontaneous rupture of spleen during peripheral stem-cell mobilization in a patient with breast cancer. Haematologica. 2000;85:559–60.PubMed
4.
Becker PS, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–9.PubMed
5.
Donadieu J, Beaupain B, Rety-Jacob F, Nove-Josserand R. Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica. 2009;94:1175–7.PubMedCrossRef
6.
Draper BK, Robbins JB, Stricklin GP. Bullous Sweet’s syndrome in congenital neutropenia: association with pegfilgrastim. J Am Acad Dermatol. 2005;52:901–5.PubMedCrossRef
7.
Schilero GJ, Oropello J, Benjamin E. Impairment in gas exchange after granulocyte colony stimulating factor (GCSF) in a patient with the adult respiratory distress syndrome. Chest. 1995;107:276–8.PubMedCrossRef
8.
Dufour C, et al. Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. Haematologica. 2010;95:684–5.PubMedCrossRef
9.
Burstein HJ, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–7.PubMedCrossRef
10.
Ishiguro H, et al. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim. Ann Oncol. 2008;19:1019–20.PubMedCrossRef
11.
Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24:2392–4.PubMedCrossRef
Metadata
Title
Pegfilgrastim overdose: case report and review of the literature
Authors
Orit Kaidar–Person
Mor Moskovitz
Tomer Charas
Wasim Alsharbati
Nissim Haim
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9751-5

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue

Original Paper

Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma

Original Paper

CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Original Paper

Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites

Original paper

Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells

Original Paper

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

Review Article

Squamous cell carcinoma of the renal pelvis associated with kidney stones: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits